Patents by Inventor Jonathan David Bortz
Jonathan David Bortz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11534458Abstract: A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.Type: GrantFiled: January 6, 2021Date of Patent: December 27, 2022Assignee: ALBION LABORATORIES, INC.Inventor: Jonathan David Bortz
-
Publication number: 20220233476Abstract: An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed iron, said agent comprising one or both of a zinc component and a chelator component, said zinc component if present comprising one or more physiologically acceptable zinc compounds and/or complexes, and said chelator component if present comprising an ion-chelating compound formulated for release distal to the primary site of iron absorption in the duodenum.Type: ApplicationFiled: April 12, 2022Publication date: July 28, 2022Inventor: Jonathan David Bortz
-
Patent number: 11331287Abstract: An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed iron, said agent comprising one or both of a zinc component and a chelator component, said zinc component if present comprising one or more physiologically acceptable zinc compounds and/or complexes, and said chelator component if present comprising an ion-chelating compound formulated for release distal to the primary site of iron absorption in the duodenum.Type: GrantFiled: May 28, 2014Date of Patent: May 17, 2022Assignee: Balchem CorporationInventor: Jonathan David Bortz
-
Publication number: 20210137975Abstract: A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.Type: ApplicationFiled: January 6, 2021Publication date: May 13, 2021Inventor: Jonathan David Bortz
-
Patent number: 10912796Abstract: A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.Type: GrantFiled: March 13, 2014Date of Patent: February 9, 2021Assignee: Albion Laboratories, Inc.Inventor: Jonathan David Bortz
-
Publication number: 20180280430Abstract: The present invention encompasses single dosage form compositions comprising component (a) and component (b). Component (a) is a combination of proteins and carbohydrates in a weight ratio that is at least about 0.5:1. Component (b) is magnesium, zinc, and/or choline. The invention also encompasses use of the single dosage form compositions to improve exercise-related performance.Type: ApplicationFiled: September 29, 2016Publication date: October 4, 2018Inventor: Jonathan David Bortz
-
Publication number: 20180161299Abstract: The present disclosure relates to pharmaceutical compositions for mammalian consumption containing essential fatty acids, protein, vitamins and choline, or combinations thereof, so constituted to optimize absorption and/or transport and/or efficiency of the co-ingredients of the composition. The pharmaceutical compositions are useful as supplements to provide nutrients to nutritionally deficient patients. The composition can contain essential fatty acids, such as EPA, DHA and/or ALA, cobalamin binding protein, such as Intrinsic Factor, vitamin B12 or a synthetic form thereof, choline, such as choline bitartrate, or combinations thereof.Type: ApplicationFiled: December 7, 2017Publication date: June 14, 2018Inventor: Jonathan David Bortz
-
Patent number: 9339475Abstract: The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.Type: GrantFiled: February 3, 2014Date of Patent: May 17, 2016Assignee: Particle Dynamics International, LLCInventors: Jonathan David Bortz, Yury Lagoviyer, Paul Timothy Brady
-
Publication number: 20160015746Abstract: A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.Type: ApplicationFiled: March 13, 2014Publication date: January 21, 2016Inventor: Jonathan David Bortz
-
Publication number: 20140364491Abstract: An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed iron, said agent comprising one or both of a zinc component and a chelator component, said zinc component if present comprising one or more physiologically acceptable zinc compounds and/or complexes, and said chelator component if present comprising an ion-chelating compound formulated for release distal to the primary site of iron absorption in the duodenum.Type: ApplicationFiled: May 28, 2014Publication date: December 11, 2014Applicant: AMIP, LLCInventor: Jonathan David Bortz
-
Publication number: 20140212505Abstract: The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.Type: ApplicationFiled: February 3, 2014Publication date: July 31, 2014Applicant: Particle Dynamics International, LLCInventors: Jonathan David Bortz, Yury Lagoviyer, Paul Timothy Brady
-
Patent number: 8679541Abstract: The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.Type: GrantFiled: February 18, 2008Date of Patent: March 25, 2014Assignee: Particle Dynamics International, LLCInventors: Jonathan David Bortz, Yury Lagoviyer, Paul Timothy Brady
-
Publication number: 20130189374Abstract: The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith.Type: ApplicationFiled: July 20, 2012Publication date: July 25, 2013Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Mitchell Kirschner
-
Publication number: 20110015150Abstract: Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency.Type: ApplicationFiled: September 27, 2010Publication date: January 20, 2011Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Mitchell I. Kirschner, David S. Hermelin
-
Publication number: 20090068190Abstract: Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane.Type: ApplicationFiled: August 27, 2008Publication date: March 12, 2009Applicant: DRUGTECH CORPORATIONInventor: Jonathan David Bortz
-
Publication number: 20090035370Abstract: A method for treating a medical condition for which quetiapine is indicated in a subject comprises comprising orally administering to the subject quetiapine or a pharmaceutically acceptable salt thereof in a daily dosage amount effective to treat said condition; wherein the quetiapine or salt thereof is administered in one to a plurality of dosage forms collectively comprising (a) a major quetiapine component in immediate-release form in a sedative effective amount, administered not earlier than about 3 hours prior to the start of a sleep period; and (b) either (i) a minor quetiapine component in extended-release, delayed extended-release or delayed pulsed-release form, wherein time of administration and release properties of the minor component provide substantial onset of release of quetiapine therefrom not earlier than about 6 hours after the start of the sleep period, or (ii) a plurality of minor quetiapine components in immediate-release form, administered sequentially during a waking period following thType: ApplicationFiled: July 31, 2008Publication date: February 5, 2009Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Michael Norman Grimshaw
-
Publication number: 20090035385Abstract: Compositions and methods for prevent, stabilize, reverse or treat disorders related to iron deficiency in a human or other animal. In a first embodiment, the composition includes about 10 mg to about 500 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; and about 5 mg to about 500 mg of one or more forms of an organic acid. In another embodiment, the composition includes about 50 to about 150 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; about 50 to about 250 mg of one or more forms of an organic acid; about 150 to about 250 mg of one or more forms of ascorbic acid; about 0.5 mg to about 1.5 mg vitamin B12; about 50 to about 150 mg intrinsic factor; and about 0.5 mg to about 1.5 mg folic acid.Type: ApplicationFiled: August 20, 2008Publication date: February 5, 2009Applicant: DRUGTECH CORPORATIONInventor: Jonathan David Bortz
-
Publication number: 20090028962Abstract: The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith.Type: ApplicationFiled: November 9, 2005Publication date: January 29, 2009Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Mitchell Kirschner
-
Publication number: 20080299050Abstract: A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenyloin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination with the phenyloin or salt thereof, to reduce pain associated with the oral mucositis. The phenyloin or salt thereof and optionally the analgesic agent can be administered in a pharmaceutical composition comprising an excipient vehicle suitable for intraoral administration, said composition being bioadhesive to an oral mucosal surface, for example having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to said surface.Type: ApplicationFiled: October 1, 2007Publication date: December 4, 2008Applicant: DrugTech CorporationInventors: Jonathan David Bortz, R. Saul Levinson, Jisheng Ge, Jeremy Donald Wang
-
Publication number: 20080299189Abstract: The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.Type: ApplicationFiled: May 23, 2008Publication date: December 4, 2008Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Michael Grimshaw, David F. Erkoboni